Trial Profile
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Methotrexate (Primary) ; Tocilizumab (Primary)
- Indications Haemophagocytic lymphohistiocytosis
- Focus Adverse reactions; Therapeutic Use
- 25 Jan 2023 Status changed from active, no longer recruiting to completed.
- 22 Sep 2021 Planned End Date changed from 28 Sep 2020 to 30 Sep 2022.
- 22 Sep 2021 Planned primary completion date changed from 28 Sep 2020 to 30 Sep 2022.